Remibrutinib (Rhapsido) maintained responses through week 52 in chronic inducible urticaria (CIndU) in the phase 3 RemIND trial, according to late-breaking data presented at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix.¹,²
The US Food & Drug Administration (FDA) approved remibrutinib on October 7, 2026, as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines.³ The approval makes the oral Bruton’s tyrosine kinase (BTK) inhibitor the only therapy indicated for SD and chronic spontaneous urticaria (CSU), which together account for more than 90% of adult chronic hives, per Novartis.³
“Up until now, the only treatments available were second-generation H1 antihistamines,” said lead RemIND investigator Giselle Mosnaim, MD, MS, allergist and immunologist at Endeavor Health and a clinical professor at the University of Chicago Pritzker School of Medicine, in an interview with HCPLive at ACAAI 2026. “For many patients, this treatment was not enough.”
Mosnaim noted some patients have both CSU and CIndU, and these patients now have a single agent approved for both conditions. Patients with CIndU alone also gain a treatment option, she added.
Remibrutinib Efficacy in RemIND Through Week 52
RemIND is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial evaluating remibrutinib 25 mg twice daily in adults with CIndU inadequately controlled by second-generation H1 antihistamines.¹ The trial enrolled 362 patients across 3 cohorts: SD, cold urticaria (ColdU), and cholinergic urticaria (CholU).¹ Patients randomized to placebo switched to remibrutinib at week 24, and the primary endpoint was the proportion of complete responders at week 12 on subtype-specific provocation tests.¹
In the SD cohort, 29.3% of patients receiving remibrutinib achieved a complete response on the Total Fric Score at week 12 vs 14.0% with placebo (P =.0229).³ Responses emerged early. At week 1, complete or partial response rates were 41.8% with remibrutinib vs 19.2% with placebo in SD and 67.4% vs 28.9% in ColdU; at week 2, rates were 65.2% vs 45.6% in CholU.¹
At week 52, complete or partial response rates among patients initially randomized to remibrutinib were 46.8% in SD, 83.3% in ColdU, and 58.2% in CholU.¹ Patients switching from placebo at week 24 reached 47.7%, 88.9%, and 69.8%, respectively.¹ Mosnaim attributed the catch-up in the switch group to the fast onset of action with remibrutinib.
“We're still learning more about the different types of CIndU,” Mosnaim said. “We’re very excited that there was such a robust response in cold urticaria, but we're still trying to better understand mechanisms of action and why the response might be more robust for cold urticaria and [why] cholinergic urticaria had a high placebo response.”
References
Mosnaim GS. Remibrutinib showed sustained efficacy and favorable safety profile through week 52 in chronic inducible urticaria. Presented at: American College of Allergy, Asthma & Immunology Annual Scientific Meeting; November 12-16, 2026; Phoenix, AZ.